What's new

EMEA-002886-PIP02-23

EMEA-002886-PIP02-23

Mar 25, 2025 - 14:40
 0
EMEA-002886-PIP02-23
EMEA-002886-PIP02-23
Read More

Tags:

Previous Article

Notifying a change of marketing status

Next Article

Guidance on the application of the amended Variations Regulation from 1 January ...

Related Posts

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate,vilanterol, Date of authorisation: 02/05/2014, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 24, 2025  0

Human medicines European public assessment report (EPAR): Tecartus, Brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025  0

EMEA-002744-PIP01-19-M01

EMEA-002744-PIP01-19-M01

Mar 25, 2025  0